Last updated on April 2020

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Brief description of study

This is a Phase 3, open-label, multicenter extension study to evaluate safety and efficacy of ozanimod in subjects with moderately to severely active Crohn's Disease.

Clinical Study Identifier: NCT03467958

Find a site near you

Start Over

Ahmed Kathrada Private Hospital

Gauteng, South Africa
  Connect »